Secretome Analysis of Host Cells Infected with Toxoplasma gondii after Treatment of Human Epidermal Growth Factor Receptor 2/4 Inhibitors
10.3347/kjp.2020.58.3.249
- Author:
Hye-Jung KIM
1
;
Hye-Jin AHN
;
Hyeweon KANG
;
Jaehui PARK
;
Seul gi OH
;
Saehae CHOI
;
Won-Kyu LEE
;
Ho-Woo NAM
Author Information
1. New Drug Development Center, OSONG Biomedical Innovation Foundation, Cheongju 28160, Korea
- Publication Type:Original Article
- From:The Korean Journal of Parasitology
2020;58(3):249-255
- CountryRepublic of Korea
- Language:English
-
Abstract:
Toxoplasma gondii, a ubiquitous, intracellular parasite of the phylum Apicomplexa, infects an estimated one-third of the human population as well as a broad range of warm-blooded animals. We have observed that some tyrosine kinase inhibitors suppressed the growth of T. gondii within host ARPE-10 cells. Among them, afatinib, human epithermal growth factor receptor 2 and 4 (HER2/4) inhibitor, may be used as a therapeutic agent for inhibiting parasite growth with minimal adverse effects on host. In this report, we conducted a proteomic analysis to observe changes in host proteins that were altered via infection with T. gondii and the treatment of HER2/4 inhibitors. Secreting proteins were subjected to a procedure of micor basic reverse phase liquid chromatography, nano-liquid chromatography-mass spectrometry, and ingenuity pathway analysis serially. As a result, the expression level of heterogeneous nuclear ribonucleoprotein K, semaphorin 7A, a GPI membrane anchor, serine/threonine-protein phosphatase 2A, and calpain small subunit 1 proteins were significantly changed, and which were confirmed further by western blot analysis. Changes in various proteins, including these 4 proteins, can be used as a basis for explaining the effects of T. gondii infections and HER2/4 inhibitors.
